DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RADIUM RA-223 DICHLORIDE

« Back to Dashboard

Clinical Trials for Radium Ra-223 Dichloride

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00699751	A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases	Completed	Bayer	Phase 3	ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.
NCT01516762	Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases	No longer available	Bayer	N/A	This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product.
NCT01618370	Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases	Completed	Bayer	Phase 3	This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product.
NCT01810770	Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis	Active, not recruiting	Bayer	Phase 3	To evaluate the safety and efficacy (Overall survival [OS]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.

Clinical Trial Conditions for Radium Ra-223 Dichloride

Condition Name

Condition Name for Radium Ra-223 Dichloride
Intervention	Trials
Prostatic Neoplasms	7
Bone Metastases	4
Prostate Cancer	3
Prostate Carcinoma Metastatic to the Bone	2

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Radium Ra-223 Dichloride
Intervention	Trials
Prostatic Neoplasms	19
Neoplasm Metastasis	8
Bone Neoplasms	3
Bone Marrow Diseases	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Radium Ra-223 Dichloride

Trials by Country

Trials by Country for Radium Ra-223 Dichloride
Location	Trials
United States	186
United Kingdom	53
Italy	50
Germany	46
Spain	30

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Radium Ra-223 Dichloride
Location	Trials
New York	11
California	11
Maryland	9
Pennsylvania	9
Washington	8

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Radium Ra-223 Dichloride

Clinical Trial Phase

Clinical Trial Phase for Radium Ra-223 Dichloride
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	12
Phase 1/Phase 2	6

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Radium Ra-223 Dichloride
Clinical Trial Phase	Trials
Active, not recruiting	8
Not yet recruiting	6
Recruiting	6

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Radium Ra-223 Dichloride

Sponsor Name

Sponsor Name for Radium Ra-223 Dichloride
Sponsor	Trials
Bayer	15
National Cancer Institute (NCI)	2
Carolina Research Professionals, LLC	2

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Radium Ra-223 Dichloride
Sponsor	Trials
Industry	20
Other	13
NIH	2

Export unavailable in trial.
Subscribe for complete access.